Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region: a single-center Asian experience.

Abstract

From March 1984 to November 2008, we performed 539 primary liver transplantations (LTs). Nineteen (19, 3.5%) were transplanted for end-stage liver disease secondary to primary biliary cirrhosis (PBC). There were 17 (89%) female and 2 (11%) male recipients. The overall mean age was 50.3 ± 6.3 yr. The mean model for end-stage liver disease, and Child-Turcotte-Pugh scores were 20.7 ± 2.1, and 11.0 ± 0.5, respectively. There were 2 (11%) United Network for Organ Sharing status 3, 16 (84%) 2B, and 1 (5%) 2A patients. Fourteen patients (14, 73.7%) underwent living donor LT, and five patients (26.3%) received deceased donor LT. The primary immunosuppression consisted of cyclosporine (n = 5) and tacrolimus (n = 14). Liver function returned to normal one month after transplantation. The overall mean follow-up was 5.8 ± 0.8 yr (range, four months to 15.7 yr). The overall one-, three-, and five-yr survival rates were 94.7%, 89.2%, and 89.2%, respectively. Without hepatitis B virus (HBV) prophylaxis, one patient acquired de novo HBV infection after receiving a graft from an anti-HBc(+) donor. Another patient developed recurrent hepatitis C infection and expired 25 months after transplantation. Our results showed that HBV prophylaxis was effective not only against de novo infection, but it also worked on pre-transplant HBV carrier with PBC and helped in virus clearance.

• Authors: Cheuk-Kwan Sun, Chao-Long Chen, Allan M Concejero, Chih-Chi Wang, Shih-Ho Wang, Yueh-Wei Liu, Chin-Hsiang Yang, Chee-Chien Yong
• Journal: Clinical transplantation (Clin Transplant) 2011 Jan-Feb Vol. 25 Issue 1 Pg. 47-53 ISSN: 1399-0012 [Electronic] Denmark
• PMID: 20560991 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2010 John Wiley & Sons A/S.

Chemical References

• Immunosuppressive Agents
• Cyclosporine
• Tacrolimus

Topics

• Adult
• Aged
• China
• Cyclosporine (therapeutic use)
• Endemic Diseases (prevention & control)
• Female
• Follow-Up Studies
• Graft Rejection (prevention & control)
• Hepatitis B (prevention & control, virology)
• Hepatitis B virus (pathogenicity)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Liver Cirrhosis, Biliary (surgery, virology)
• Liver Transplantation
• Living Donors
• Male
• Middle Aged
• Survival Rate
• Tacrolimus (therapeutic use)
• Treatment Outcome